Haemonetics (HAE) Stock Price, News & Analysis

Company Overview

Haemonetics Corporation (NYSE: HAE) is a medical technology company that develops and supplies products and software for blood management. Its solutions are used to collect, process, manage and analyze blood and blood components, helping healthcare providers and blood and plasma collection organizations improve the availability, safety and efficiency of transfusion-related care.

The company’s portfolio includes plasma and blood component collection systems, disposable collection and processing kits, surgical blood recovery and autotransfusion systems, and technologies used to assess coagulation and hemostasis. Haemonetics also provides software and related services that support blood-center operations, hospital transfusion management and inventory workflows. Its products include the NexSys and PCS plasma collection systems, Cell Saver blood recovery systems and TEG hemostasis analyzers.

Founded in 1971, Haemonetics serves hospitals, blood centers, plasma collectors and other healthcare organizations internationally. The company operates across North America, Europe and other global markets through direct operations and distribution relationships. Its corporate headquarters are in Boston, Massachusetts.

Key Stats

• Today's Range: $103.65 to $106.26
• 50-Day Range: $82.68 to $108.94
• 52-Week Range: $48.17 to $110.45
• Volume: 652,646 shs
• Average Volume: 531,385 shs
• Market Capitalization: $4.77 billion
• P/E Ratio: 51.40
• Dividend Yield: N/A
• Price Target: $99.78
• Consensus Rating: Moderate Buy

Haemonetics Stock Analysis - MarketRank™

Haemonetics scored higher than 33% of companies evaluated by MarketBeat, and ranked 712th out of 888 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Haemonetics has received a consensus rating of Moderate Buy. The company's average rating score is 2.73, and is based on 1 strong buy rating, 6 buy ratings, 4 hold ratings, and no sell ratings.

Upside/Downside

The consensus price target for Haemonetics is close to its current price, suggesting limited near-term upside or downside.

Amount of Analyst Coverage

Haemonetics has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 1.9 / 5
• Proj. Earnings Growth: 8.32%

Earnings Growth

Earnings for Haemonetics are expected to grow by 8.32% in the coming year, from $5.29 to $5.73 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Haemonetics is 51.40, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 44.65.

Price to Earnings Ratio vs. Sector

The P/E ratio of Haemonetics is 51.40, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 274.32.

Price to Earnings Growth Ratio

Haemonetics has a PEG Ratio of 2.10. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

Haemonetics has a P/B Ratio of 6.12. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

7.69% of the float of Haemonetics has been sold short.

Short Interest Ratio / Days to Cover

Haemonetics has a short interest ratio ("days to cover") of 5.69.

Change versus previous month

Short interest in Haemonetics has recently increased by 19.60%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Haemonetics does not currently pay a dividend.

Dividend Growth

Haemonetics does not have a long track record of dividend growth.

News and Social Media

• Score: 2.0 / 5
• News Sentiment: 0.19

News Sentiment

Haemonetics has a news sentiment score of 0.19. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.43 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 7 news articles for Haemonetics this week, compared to 5 articles on an average week.

Search Interest

Only 2 people have searched for HAE on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Haemonetics insiders have not sold or bought any company stock.

Percentage Held by Insiders

2.07% of the stock of Haemonetics is held by insiders.

Percentage Held by Institutions

99.67% of the stock of Haemonetics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/06/2026
• Today: 10/06/2026
• Next Earnings (Estimated): 11/05/2026
• Fiscal Year End: 3/31/2027

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Healthcare
• Industry: Healthcare Equipment & Supplies
• Sub-Industry: Healthcare Equipment
• Current Symbol: NYSE:HAE
• CIK: 313143
• Web: www.haemonetics.com
• Phone: (781) 848-7100
• Fax: 781-848-5106
• Employees: 3,009
• Year Founded: 1971

Price Target and Rating

• Average Price Target for Haemonetics: $99.78
• High Price Target: $125.00
• Low Price Target: $78.00
• Potential Upside/Downside: -4.8%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.73
• Research Coverage: 11 Analysts

Profitability

• EPS (Trailing Twelve Months): $2.04
• Trailing P/E Ratio: 51.40
• Forward P/E Ratio: 19.82
• P/E Growth: 2.1
• Net Income: $97.31 million
• Net Margins: 7.12%
• Pretax Margin: 9.65%
• Return on Equity: 27.55%
• Return on Assets: 9.65%

Debt

• Debt-to-Equity Ratio: 1.40
• Current Ratio: 3.08
• Quick Ratio: 1.91

Sales & Book Value

• Annual Sales: $1.33 billion
• Price / Sales: 3.58
• Cash Flow: $7.59 per share
• Price / Cash Flow: 13.81
• Book Value: $17.14 per share
• Price / Book: 6.12

Miscellaneous

• Outstanding Shares: 45,500,000
• Free Float: 44,555,000
• Market Cap: $4.77 billion
• Optionable: Optionable
• Beta: 0.61